Abdominal aortic aneurysmal (AAA) repair in patients with concomitant cancer is controversial due to increased comorbidity and reduced life expectancy in this specific patient group. This literature review aims to investigate the evidence supporting one treatment modality over another (endovascular aortic repair (EVAR) or open repair (OR)), as well as treatment strategy (staged AAA-, cancer first or simultaneous procedures) in patients with AAA and concomitant cancer.
Methods
Literature review, including studies published from 2000 to 2021 on surgical treatment in patients with AAA and concomitant cancer and related outcomes (30-day morbidity/complications as well as 30-day and 3-year mortality).
Results
24 studies comprising 560 patients undergoing surgical treatment of AAA and concomitant cancer were included. Of these, 220 cases were treated with EVAR and 340 with OR. Simultaneous procedures were performed in 190 cases, 370 received staged procedures. The 30-day mortality for EVAR versus OR was 1% and 8%, corresponding to a relative risk (RR) of 0.11 (95% CI: 0.03–0.46, p = 0.002). No difference in mortality was observed between staged versus simultaneous procedure nor between AAA-first versus cancer-first strategy, RR 0.59 (95% CI: 0.29–1.1, p = 0.13) and 0.88 (95% CI 0.34–2.31, p = 0.80), respectively. Overall, 3-year mortality was 21% for EVAR and 39% for OR from 2000–2021, while the mortality up to 3 years after EVAR within recent years (2015–2021) was 16%.
Conclusion
This review supports EVAR treatment as first choice if suitable. No consensus was established on treating either the aneurysm or the cancer first or simultaneously. Long-term mortality after EVAR was comparable to non-cancer patients within recent years.
PilleronSSoto-Perez-de-CelisEVignatJ, et al.Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050. Int J Cancer2021; 148(3): 601–608.
2.
PilleronSSarfatiDJanssen-HeijnenM, et al.Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer2019; 144(1): 49–58.
3.
TreskaVMolacekJCertikB, et al.Management of concomitant abdominal aortic aneurysm and intra-abdominal, retroperitoneal malignancy. In Vivo2021; 35(1): 517–523.
4.
OnoharaTKyuragiRInoueK, et al.Late-onset malignant neoplasms and their prognostic factors after abdominal aortic aneurysm repair. Ann Vasc Surg2019; 56: 194–201.
5.
KouvelosGNPatelisNAntoniouGA, et al.Management of concomitant abdominal aortic aneurysm and colorectal cancer. J Vasc Surg2016; 63(5): 1384–1393.
6.
MaedaKOhkiTKanaokaY, et al.Current surgical management of abdominal aortic aneurysm with concomitant malignancy in the endovascular era. Surg Today2016; 46(8): 985–994.
7.
ShalhoubJNaughtonPLauN, et al.Concurrent colorectal malignancy and abdominal aortic aneurysm: a multicentre experience and review of the literature. Eur J Vasc Endovasc Surg2009; 37(5): 544–556.
8.
MohandasSMalikHTSyedI. Concomitant abdominal aortic aneurysm and gastrointestinal malignancy: evolution of treatment paradigm in the endovascular era - review article. Int J Surg2013; 11(2): 112–115.
9.
KimHChoSIWonS, et al.The prevalence of concomitant abdominal aortic aneurysm and cancer. J Clin Med2021; 10(17): 3847.
10.
DeSantisCELinCCMariottoAB, et al.Cancer treatment and survivorship statistics. CA Cancer J Clin2014; 64(4): 252–271.
11.
WilkinsTMcMechanDTalukderA. Colorectal cancer screening and prevention. Am Fam Physician2018; 97(10): 658–665.
12.
LiuSVReckMMansfieldAS, et al.Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol2021; 39(6): 619–630.
13.
MokTSKWuYLKudabaI, et al.Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet2019; 393(10183): 1819–1830.
14.
BrahmerJReckampKLBaasP, et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med2015; 373(2): 123–135.
15.
GrotheyASargentDGoldbergRM, et al.Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol2004; 22(7): 1209–1214.
16.
PiawahSVenookAP. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer2019; 125(23): 4139–4147.
17.
WanhainenAVerziniFVan HerzeeleI, et al.Editor’s choice—european society for vascular surgery (esvs) 2019 clinical practice guidelines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endovasc Surg2019; 57(1): 8–93.
18.
CaineGJStonelakePSLipGYH, et al.The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia2002; 4(6): 465–473.
19.
NaviBBReinerASKamelH, et al.Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol2017; 70(8): 926–938.
20.
WangJKimYDKimCH. Incidence and risk of various types of arterial thromboembolism in patients with cancer. Mayo Clin Proc2021; 96(3): 592–600.
21.
KumarRDattaniNAsaadO, et al.Meta-analysis of outcomes following aneurysm repair in patients with synchronous intra-abdominal malignancy. Eur J Vasc Endovasc Surg2016; 52(6): 747–756.
22.
de GuerreLVenermoMManiK, et al.Paradigm shifts in abdominal aortic aneurysm management based on vascular registries. J Intern Med2020; 288(1): 38–50.
23.
Budtz-LillyJWanhainenAManiK. Outcomes of endovascular aortic repair in the modern era. J Cardiovasc Surg (Torino)2018; 59(2): 180–189.
24.
PageMJ MJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021; 372: n71. DOI: 10.1136/bmj.n71, https://www.prisma-statement.org2020.
BerteroLMassaFMetovicJ, et al.Eighth edition of the UICC classification of malignant tumours: an overview of the changes in the pathological TNM classification criteria-what has changed and why?Virchows Arch2018; 472(4): 519–531.
27.
FengSHYangST. The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations. Diagn Interv Radiol2019; 25(4): 270–279.
28.
AkkocaANYanıkSOzdemirZT, et al.TNM and modified dukes staging along with the demographic characteristics of patients with colorectal carcinoma. Int J Clin Exp Med2014; 7(9): 2828–2835.
29.
BracaleUDi NuzzoMMBracaleUM, et al.Sequential minimally invasive treatment of concomitant abdominal aortic aneurysm and colorectal cancer: a single-center experience. Ann Vasc Surg2021; 78: P226–P232.
30.
ZhangBWuKLiuY, et al.Synchronous gastrointestinal tumor and abdominal aortic aneurysm or dissection treated with endovascular aneurysm repair followed by tumor resection. Gastroenterol Res Pract2019; 2019: 8087256.
31.
GattusoRPiconeVBelliC, et al.Treatment of abdominal aortic aneurysms and coexisting cancer: Endovascular versus traditional approach. Ital J Vasc Endovasc Surg2019; 26(2): 76–80.
32.
IlluminatiGPizzardiGPasquaR, et al.Endovascular exclusion of abdominal aortic aneurysms and simultaneous resection of colorectal cancer. Ann Vasc Surg2019; 58: 1–6.
33.
MatsumotoTMatsudaDHonmaK, et al.One-stage procedure for concomitant abdominal aortic aneurysm and gastric cancer. Anticancer Res2015; 35(12): 6909–6912.
34.
AmatoBEspositoGSerraR, et al.One-step mini-invasive treatment of abdominal aortic-iliac aneurysm associated with colo-rectal cancer. Int J Surg2014; 12(Suppl 2): S193–S196.
35.
SpanosCPTsoulfasGGeorgantisG, et al.Management of concurrent colorectal cancer and vascular disease in the endovascular era. Tech Coloproctol2011; 15(Suppl 1): S55–S58.
36.
HabetsJButhJCuypersPWM, et al.Infrarenal abdominal aortic aneurysm with concomitant urologic malignancy: treatment results in the era of endovascular aneurysm repair. Vascular2010; 18(1): 14–19.
37.
VeraldiGFMinicozziAGencoB, et al.[Endovascular treatment (EVAR) in patients with abdominal aortic aneurysms and synchronous neoplasms]. Chir Ital2008; 60(1): 23–31.
38.
BorzellinoGGiovinazzoFMinicozziAM, et al.Concomitant pulmonary carcinoma and abdominal aortic aneurysm: therapeutic strategies. Surg Today2008; 38(6): 512–516.
39.
LinPHBarshesNRAlboD, et al.Concomitant colorectal cancer and abdominal aortic aneurysm: evolution of treatment paradigm in the endovascular era. J Am Coll Surg2008; 206(5): 1065–1073; discussion 1074-1075.
40.
PorcelliniMNastroPBracaleU, et al.Endovascular versus open surgical repair of abdominal aortic aneurysm with concomitant malignancy. J Vasc Surg2007; 46(1): 16–23.
41.
SuffatLPGuffantiPRebecchiF, et al.Abdominal aortic aneurysm and concomitant malignancy: what treatment?Ann Ital Chir2006; 77(4): 345–349.
42.
CastelliPCaronnoRPiffarettiG, et al.Synchronous repair for abdominal aortic aneurysms and intra-abdominal malignant diseases. Ital J Vasc Endovascular Surg2006; 13(2): 83–86.
43.
SettembriniPGTassinariLMercandalliG, et al.Abdominal aortic aneurysms and concomitant neoplastic diseases. EVAR: a new option for surgical timing. Ital J Vasc Endovascular Surg2006; 13(4): 183–186.
44.
PedrazzaniCVeraldiGFTasselliS, et al.Surgical treatment of gastric cancer with coexistent abdominal aortic aneurysm. personal experience and literature review. Hepatogastroenterology2006; 53(72): 973–975.
45.
VeraldiGFTasselliSDe ManzoniG, et al.Surgical treatment of abdominal aortic aneurysm with concomitant renal cell carcinoma: a single-centre experience with review of the literature. J Cardiovasc Surg (Torino)2006; 47(6): 643–649.
46.
GregoFLepidiSBassiP, et al.Simultaneous surgical treatment of abdominal aortic aneurysm and carcinoma of the bladder. J Vasc Surg2003; 37(3): 607–614.
47.
MatsumotoKMurayamaTNagasakiK, et al.One-stage surgical management of concomitant abdominal aortic aneurysm and gastric or colorectal cancer. World J Surg2002; 26(4): 434–437.
48.
BaxterNNNoelAACherryK, et al.Management of patients with colorectal cancer and concomitant abdominal aortic aneurysm. Dis Colon Rectum2002; 45(2): 165–170.
49.
BachooPCooperGEngesetJ, et al.Management of synchronous infrarenal aortic disease and large bowel cancer: a North-east of Scotland experience. Eur J Vasc Endovasc Surg2000; 19(6): 614–618.
50.
Revuelta SueroSMartínez LópezIHernández MateoM, et al.Outcomes of the repair of 1000 abdominal aortic aneurysms in the endovascular era. Ann Vasc Surg2019; 59: 63–72.
51.
de la MotteLJensenLPVogtK, et al.Outcomes after elective aortic aneurysm repair: a nationwide danish cohort study 2007-2010. Eur J Vasc Endovasc Surg2013; 46(1): 57–64.
52.
PowellJTSweetingMJUlugP, et al.Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years. Br J Surg2017; 104(3): 166–178.
53.
PrinssenMVerhoevenELGButhJ, et al.A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med2004; 351(16): 1607–1618.
54.
PatelRSweetingMJPowellJT, et al.Endovascular versus open repair of abdominal aortic aneurysm in 15-years’ follow-up of the UK endovascular aneurysm repair trial 1 (EVAR trial 1): a randomised controlled trial. Lancet2016; 388(10058): 2366–2374.
55.
LederleFAFreischlagJAKyriakidesTC, et al.Long-term comparison of endovascular and open repair of abdominal aortic aneurysm. N Engl J Med2012; 367(21): 1988–1997.
56.
GreenhalghRMBrownLCKwongGPS, et al.Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial. Lancet2004; 364(9437): 843–848.
57.
HisadaYMackmanN. Cancer-associated pathways and biomarkers of venous thrombosis. Blood2017; 130(13): 1499–1506.
58.
FernandesCJMorinagaLTKAlvesJLJ, et al.Cancer-associated thrombosis: the when, how and why. Eur Respir Rev2019; 28(151): 180119.
59.
GervasoLDaveHKhoranaAA. Venous and arterial thromboembolism in patients with cancer: JACC: CardioOncology state-of-the-art review. JACC CardioOncol2021; 3(2): 173–190.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
